Celestia (tia) S. Higano

Q: What Schools Are Affiliated With Celestia (tia) S. Higano

Celestia (tia) S. Higano is affiliated with the following schools: Institute of Cancer Research, Université de Montréal, University of British Columbia, Marmara University, University of California, Davis, Oregon Health & Science University, University of Washington

Celestia (tia) S. Higano's AcademicInfluence.com Rankings

Medical

#2048

World Rank

#2442

Historical Rank

Urology

#12

World Rank

#13

Historical Rank

Oncology

#110

World Rank

#114

Historical Rank

Pharmacology

#210

World Rank

#250

Historical Rank

medical Degrees

Celestia (tia) S. Higano

Philosophy

#6013

World Rank

#8972

Historical Rank

Logic

#3207

World Rank

#4330

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Celestia (tia) S. Higano Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Celestia (tia) S. Higano's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. (2010) (4808)
Abiraterone in metastatic prostate cancer without previous chemotherapy. (2013) (2446)
Enzalutamide in metastatic prostate cancer before chemotherapy. (2014) (2357)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer (2009) (2012)
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. (2008) (1370)
Guideline for the management of clinically localized prostate cancer: 2007 update. (2007) (1186)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. (2006) (1082)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. (2015) (1059)
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (1026)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study (2010) (1004)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
Quantitative and stoichiometric analysis of the microRNA content of exosomes (2014) (816)
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009) (800)
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. (2007) (721)
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B (2012) (668)
Prostate Cancer, Version 1.2016. (2016) (586)
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine (2011) (512)
Intermittent versus continuous androgen deprivation in prostate cancer. (2013) (471)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. (2005) (455)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. (2013) (431)
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (429)
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. (2012) (358)
Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer (2016) (326)
Intermittent androgen suppression for rising PSA level after radiotherapy. (2012) (326)
Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study (2010) (316)
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. (2003) (306)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration (2020) (298)
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. (2017) (277)
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology (2014) (277)
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. (2016) (265)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer (2016) (255)
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). (2014) (254)
Prostate cancer, version 2.2014. (2014) (252)
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. (2003) (252)
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. (2007) (250)
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. (2014) (250)
Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. (2003) (234)
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (230)
Erectile function outcome reporting after clinically localized prostate cancer treatment. (2007) (227)
Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapy (2004) (216)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study (2020) (211)
Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer (2008) (193)
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. (2013) (184)
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. (2009) (183)
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. (2015) (176)
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. (2015) (176)
LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics (2017) (172)
Elevation of cytokine levels in cachectic patients with prostate carcinoma (2003) (170)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). (2010) (163)
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. (2019) (160)
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. (1996) (151)
Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. (1991) (150)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. (2013) (148)
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. (2003) (141)
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. (2015) (140)
Histopathological assessment of prostate cancer bone osteoblastic metastases. (2008) (133)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer (2016) (126)
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer (2015) (124)
Multimarker circulating DNA assay for assessing blood of prostate cancer patients. (2009) (120)
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. (2014) (120)
Castration-resistant prostate cancer: from new pathophysiology to new treatment. (2014) (118)
Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy (2013) (117)
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. (2015) (112)
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome (2015) (110)
Prostate cancer, version 1.2014. (2013) (108)
Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. (1990) (108)
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity (2010) (105)
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? (2008) (102)
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort (2016) (102)
Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone (2012) (99)
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases (2007) (97)
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. (2004) (97)
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). (2012) (96)
A randomized trial of cognitive rehabilitation in cancer survivors. (2013) (91)
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. (2016) (89)
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens (2018) (89)
Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. (2014) (88)
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. (2013) (88)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. (2013) (87)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells (2010) (87)
Metastases of prostate cancer express estrogen receptor-beta. (2004) (84)
A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors (2007) (80)
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. (2016) (80)
Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. (2004) (79)
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. (2005) (79)
Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. (1992) (78)
Germline and Somatic Mutations in Prostate Cancer for the Clinician. (2019) (78)
Colorectal carcinoma: detection with indium-111 anticarcinoembryonic-antigen monoclonal antibody ZCE-025. (1987) (77)
C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases: Relative Findings and Response to Therapy (2011) (76)
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. (1991) (75)
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. (2014) (75)
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. (2007) (75)
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. (2020) (74)
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. (2021) (74)
“Osteoporosis in Men with Prostate Carcinoma Receiving Androgen-Deprivation Therapy: Recommendations for Diagnosis and Therapies,” (2004) (74)
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer (2007) (73)
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. (2016) (73)
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. (2009) (72)
Molecular Alterations in Prostate Carcinomas that Associate with In vivo Exposure to Chemotherapy: Identification of a Cytoprotective Mechanism Involving Growth Differentiation Factor 15 (2007) (72)
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. (2006) (67)
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL (2017) (65)
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. (2017) (65)
Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. (1997) (65)
Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. (1990) (65)
Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC) (2008) (64)
Naturally occurring prostate cancer antigen‐specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancer (2001) (63)
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer (2013) (63)
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide (2017) (63)
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. (2014) (62)
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. (2010) (62)
Venocclusive disease of the liver: prospective study of US evaluation. (1992) (61)
A PHASE 3 TRIAL OF GVAX IMMUNOTHERAPY FOR PROSTATE CANCER VS. DOCETAXEL PLUS PREDNISONE IN ASYMPTOMATIC, CASTRATION-RESISTANT PROSTATE CANCER (CRPC) (2009) (60)
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration‐resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series (2013) (60)
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. (2010) (60)
New and emerging agents for the treatment of castration-resistant prostate cancer. (2011) (59)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (59)
Androgen deprivation therapy: monitoring and managing the complications. (2006) (58)
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases (2013) (57)
Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687 (2015) (56)
Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (2012) (56)
Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). (2009) (54)
Acceptability of Fitbit for Physical activity Tracking within Clinical Care Among Men with Prostate Cancer (2016) (54)
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. (2020) (54)
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). (2011) (53)
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. (2012) (52)
Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. (2009) (52)
Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. (2012) (52)
Analysis and sorting of prostate cancer cell types by flow cytometry (1999) (51)
Estrogenic side effects of androgen deprivation therapy. (2007) (50)
A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T (2014) (50)
Conventional treatments of localized prostate cancer. (2008) (48)
Management of bone loss in men with prostate cancer. (2003) (48)
Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). (2009) (47)
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer (2019) (47)
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations (2020) (47)
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel (2007) (47)
Expression of the human cachexia‐associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia (2003) (44)
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. (2015) (43)
Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate Cancer (2004) (43)
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial (2015) (41)
Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. (2016) (40)
Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer (2016) (40)
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high‐risk prostate cancer (2010) (40)
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. (2012) (40)
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial (2018) (40)
Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression. (2012) (39)
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. (2015) (39)
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. (2009) (39)
Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. (2003) (39)
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. (2015) (39)
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). (2020) (37)
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (2018) (37)
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. (2019) (37)
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. (2006) (36)
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). (2013) (35)
Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC) (2005) (35)
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases (2013) (35)
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (2016) (34)
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. (2008) (34)
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. (2012) (34)
Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer (2004) (34)
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer (2020) (33)
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial (2019) (33)
SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). (2012) (32)
Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. (2000) (32)
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. (2006) (32)
Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma (2005) (31)
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors (2013) (30)
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. (2019) (29)
Intermittent androgen deprivation: clinical experience and practical applications. (2006) (29)
A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). (2009) (29)
A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC) (2004) (28)
Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC) (2008) (28)
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. (2019) (28)
Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors (2016) (28)
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. (2009) (27)
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. (2018) (27)
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone‐sensitive prostate cancer (2018) (27)
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. (2015) (26)
Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). (2011) (25)
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. (2020) (25)
Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes (2014) (25)
A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. (2011) (25)
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. (2012) (25)
Potential use of custirsen to treat prostate cancer (2013) (24)
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer (2021) (24)
Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T (2014) (24)
Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. (2010) (24)
The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. (2015) (24)
Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals (2022) (23)
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration‐resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial (2017) (23)
Gallbladder sludge formation after bone marrow transplant: Sonographic observations (2005) (22)
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). (2012) (22)
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling (2016) (21)
Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. (2015) (21)
Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC) (2005) (21)
Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling (2018) (20)
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA). (2020) (20)
Mismatch repair enzyme expression in primary and castrate resistant prostate cancer (2016) (19)
Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. (2018) (19)
Impact of androgen deprivation therapy on mood, cognition, and risk for AD. (2020) (19)
Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. (2015) (19)
Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer (2013) (19)
Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. (2016) (19)
Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer (2020) (19)
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility (2017) (19)
Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. (1992) (19)
Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. (1988) (18)
Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients? (2019) (18)
A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (2013) (18)
Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners (2017) (17)
A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (2014) (17)
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer (2020) (17)
Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC) (2007) (17)
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer (2011) (17)
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. (2019) (17)
Prostate Cancer–Associated Gene Expression Alterations Determined from Needle Biopsies (2009) (17)
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. (2012) (17)
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer (2018) (16)
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. (2018) (16)
OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. (2009) (16)
Combined treatment with chemotherapy and neutron irradiation for limited non-small-cell lung cancer: a Southwest Oncology Group Study. (1987) (16)
Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study. (2015) (15)
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. (2015) (15)
Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis (1987) (15)
Complications of Androgen Deprivation Therapy: Prevention and Treatment (2004) (15)
Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors (2015) (15)
Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. (2011) (15)
Antitumor activity of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term follow-up of a phase I/II study. (2011) (14)
New treatment options for patients with metastatic castration-resistant prostate cancer. (2012) (14)
Integration of immunotherapy into the management of advanced prostate cancer. (2012) (14)
Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. (2012) (14)
Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer. (2020) (14)
Intermittent versus continuous androgen deprivation therapy. (2014) (14)
ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). (2015) (13)
Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC). (2012) (13)
SRRM 4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer (2015) (12)
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. (2003) (12)
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer (2021) (12)
Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. (2019) (12)
Annual zoledronic acid: is less more? (2007) (12)
Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer (2013) (12)
Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates (2017) (12)
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. (2015) (11)
Intermittent Androgen Deprivation Therapy-An Important Treatment Option for Prostate Cancer. (2016) (11)
Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. (2008) (11)
Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy (2015) (11)
Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management (2018) (11)
Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). (2014) (11)
SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). (2011) (10)
Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC). (2011) (10)
ARN-509 in Men with High Risk Non-Metastatic Castration-Resistant Prostate Cancer (2012) (10)
The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer (2007) (10)
Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer. (2014) (10)
Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC). (2006) (10)
Treatment options for muscle‐invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (2008) (10)
Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916 (2008) (10)
Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. (2014) (10)
Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort (2021) (9)
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421) (2018) (9)
Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—Phase III. (2012) (9)
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF (2015) (9)
Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. (2019) (9)
A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study (2004) (9)
A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis (2007) (9)
Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial. (2015) (8)
Sipuleucel-T product characterization across different disease states of prostate cancer. (2012) (8)
Use of interferon alfa-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation. (1993) (8)
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy (2021) (8)
Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. (2020) (8)
648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer (2006) (8)
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial. (2017) (8)
ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer. (2016) (8)
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data (2020) (8)
A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate. (2017) (8)
Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone‐Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database (2017) (8)
Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: data from PROCEED. (2014) (7)
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations (2021) (7)
OVERALL SURVIVAL ANALYSIS OF AFRICAN AMERICAN AND CAUCASIAN PATIENTS RECEIVING SIPULEUCEL‐T: PRELIMINARY DATA FROM THE PROCEED REGISTRY: PD24‐12 (2017) (7)
Prophylactic cranial irradiation for limited non‐small cell lung cancer (1988) (7)
Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients. (1988) (7)
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study (2021) (7)
755OA RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE DOCETAXEL/PREDNISONE (DP) TO DP PLUS CUSTIRSEN IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). (2014) (7)
765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL. (2014) (7)
Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts). (2013) (7)
Randomized phase III trial of thalidomide (Th) or placebo (P) for non-metastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy (2008) (7)
Genetic factors associated with prostate cancer conversion from active surveillance to treatment (2021) (7)
Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. (2020) (6)
Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer. (2007) (6)
Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis. (2019) (6)
To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer. (2014) (6)
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors (2022) (6)
Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach (2021) (6)
767PRESPONSE RATES AND OUTCOMES WITH ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND VISCERAL DISEASE IN THE PREVAIL TRIAL. (2014) (6)
Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162). (2006) (6)
Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial (2004) (6)
A Phase 2 Study of an Allogeneic GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine in Patients with Metastatic Hormone-Refractory Prostate Cancer (2004) (6)
Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer. (2010) (6)
Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. (2013) (5)
Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). (2016) (5)
A Novel miRNA-Based Predictive Model for Biochemical Failure Following Post-Prostatectomy Salvage Radiation Therapy (2015) (5)
Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis (2014) (5)
Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. (2010) (5)
Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors (2019) (5)
Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial. (2015) (4)
A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). (2004) (4)
PII-LBA10 A MULTICENTER PHASE 2 STUDY OF ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN MEN WITH NONMETASTATIC (M0) OR METASTATIC (M1) CASTRATION-RESISTANT PROSTATE CANCER (CRPC): THE STRIVE TRIAL (2015) (4)
Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. (2014) (4)
Abstract of ASTRO scientific paper to be presentedCombined 5-fluorouracil and irradiation for the treatment of invasive bladder cancer (1989) (4)
Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. (1988) (4)
761PDNOVEL ANTIANDROGEN ARN-509 IN HIGH-RISK NON-METASTATIC (M0) CASTRATION-RESISTANT PROSTATE CANCER (CRPC). (2014) (4)
7002 ORAL Time to Disease-related Pain After Sipuleucel-T in Asymptomatic Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Results From 3 Randomized Phase III Trials (2011) (4)
Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. (1992) (4)
Abstract CT329: Phase I study of the PI3Kβ/δ inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding (2015) (4)
Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials (2016) (4)
517 oral QOL / OUTCOMES OF AN INTERNATIONAL PHASE 3 TRIAL OF INTERMITTENT V CONTINUOUS HORMONE THERAPY FOR RELAPSED PROSTATE CA (2011) (4)
AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). (2018) (4)
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
1099 LONG-TERM EFFICACY RESULTS FROM THE PHASE 1-2 STUDY OF MDV3100 IN PRE- AND POST-DOCETAXEL ADVANCED PROSTATE CANCER (2011) (4)
Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic (2020) (4)
Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer (2005) (4)
Assessing the nutritional needs of men with prostate cancer (2019) (4)
Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. (2019) (4)
Sipuleucel-T product characterization across different disease states of prostate cancer. (2012) (4)
Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer. (2010) (4)
Phase II evaluation of amonafide in renal cell carcinoma (1991) (3)
progression-free survival: Results from ACRIN 6687 (2015) (3)
The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer. (2017) (3)
Pleuroperitoneal Communication Associated with Malignant Ascites A Potential Cause for New Pleural Effusion Suggestive of Pulmonary Embolism (1990) (3)
PD27-05 INTERMITTENT ANDROGEN DEPRIVATION WITH THE GONADOTROPHIN−RELEASING HORMONE ANTAGONIST DEGARELIX (2014) (3)
New developments in the treatment of castration-resistant prostate cancer. (2014) (3)
Serologic surveillance for evidence of deep disseminating fungal infections in bone marrow transplantation recipients. (1988) (3)
803TiPERA 223-A PHASE 3 TRIAL OF RADIUM-223 DICHLORIDE (RA-223) IN COMBINATION WITH ABIRATERONE ACETATE (AA) AND PREDNISONE IN THE TREATMENT OF ASYMPTOMATIC OR MILDLY SYMPTOMATIC CHEMOTHERAPY-NAïVE PATIENTS WITH BONE-PREDOMINANT METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC). (2014) (3)
762PDIMPACT OF ENZALUTAMIDE ON SKELETAL RELATED EVENTS (SRES), PAIN AND QUALITY OF LIFE (QOL) IN THE PREVAIL TRIAL. (2014) (3)
PI-05 LATE-BREAKING ABSTRACT: THE PREVAIL STUDY: PRIMARY AND NON-VISCERAL / VISCERAL DISEASE SUBGROUP RESULTS FOR ENZALUTAMIDE-TREATED MEN WITH METASTATIC PROSTATE CANCER (MPC) THAT HAD PROGRESSED ON ADT (2014) (3)
PD27-04 SIPULEUCEL-T-INDUCED ANTIGEN SPREAD: IMMUNE RESPONSE TO PROSTATE-SPECIFIC ANTIGEN CORRELATES WITH IMPROVED OVERALL SURVIVAL (2014) (3)
674 INTEGRATED SAFETY RESULTS FROM FOUR RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF SIPULEUCEL-T (2010) (3)
Role of detection of metastatic disease as a leading cause of screening failure in an ongoing phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC). (2011) (3)
Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium. (2010) (3)
Sexual Health After Cancer Therapy. (2016) (3)
MP73-04 THE ASSOCIATION BETWEEN STATIN USE AND OUTCOMES IN PATIENTS INITIATING ANDROGEN DEPRIVATION THERAPY (2015) (3)
Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer (2009) (3)
Genitourinary tumors, prostate (2012) (3)
Need for awareness and monitoring of ocular toxicities (OT) due to weekly docetaxel administration: experience during a trial of neoadjuvant docetaxel (D) and mitoxantrone (M) for patients with high-risk prostate cancer (PC) (2004) (3)
Androgen deprivation for prostate cancer: when and how, the good and the bad. (2013) (3)
A weekly cisplatin‐based induction regimen for extensive non‐small cell lung cancer. A southwest oncology group study (1991) (3)
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421 (2017) (3)
MP70-02 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED (2013) (3)
Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2019) (3)
Current status of treatment for patients with metastatic prostate cancer. (2005) (2)
Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience. (2015) (2)
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach (2022) (2)
Sexual rehabilitation recommendations for prostate cancer survivors and their partners from a biopsychosocial Prostate Cancer Supportive Care Program (2021) (2)
Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer. (2019) (2)
Does nonmetastatic castration-resistant prostate cancer still exist? (2018) (2)
Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (2)
Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry. (2015) (2)
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T (2014) (2)
Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: Preliminary results from ACRIN 6687. (2013) (2)
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study) (2022) (2)
Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry. (2016) (2)
A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation (2019) (2)
Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts). (2014) (2)
Intermittent Androgen Deprivation with the GnRH Antagonist Degarelix in Men with Biochemical Relapse of Prostate Cancer (2015) (2)
Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use. (2016) (2)
Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC). (2016) (2)
Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED. (2013) (2)
Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. (2020) (2)
A Clinician's Guide to Targeted Precision Imaging in Patients With Prostate Cancer (RADAR VI) (2022) (2)
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. (2021) (2)
Androgen-deprivation therapy for prostate cancer. (2003) (2)
Repeated dose samarium 153 lexidronam in patients with prostate cancer bone metastases (2005) (2)
Microbes Battle Back (1997) (2)
905 ANTITUMOUR ACTIVITY OF MDV3100 IN A PHASE 1-2 STUDY OF ADVANCED PROSTATE CANCER (2010) (2)
Phase I trial of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in combination with docetaxel (DTX) in patients (pts) with advanced solid tumors, including castration-resistant prostate cancer (CRPC). (2014) (2)
Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry. (2018) (2)
Clinic Utilization and Characteristics of Patients Accessing a Prostate Cancer Supportive Care Program’s Sexual Rehabilitation Clinic (2020) (2)
Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer (2010) (2)
Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation (2015) (2)
A Multimarker Circulating DNA Assay for Assessing Prostate Cancer Patients’ Blood (2009) (2)
Impact of Prior Radiation Treatment on Sipuleucel-T Product Parameters in PROCEED Patients (2014) (1)
NCCN Prostate Cancer , Version 2 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
Use of Bone Health Agents (BHAs) in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Radium-223 after Abiraterone: An Interim Review of Reassure (2019) (1)
Genomic analysis of prostate cancer. (2013) (1)
Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. (2015) (1)
A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD). (2013) (1)
Treatment of chronic myeloid leukemia relapsing after allogenic bone marrow transplantation (1998) (1)
Clinical Validation of a Circulating Tumor Cell Assay Using Density Centrifugation and Automated Immunofluorescence Microscopy. (2022) (1)
The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer. (2015) (1)
Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. (2018) (1)
Scintigraphic detection of gastric and pancreatic carcinomas with In-111 ZCE 025 monoclonal antibody (2005) (1)
Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel (2005) (1)
Pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling. (2016) (1)
Implementation of an electronic patient reported outcome system in a prostate cancer urology clinic. (2018) (1)
580 ANTITUMOR ACTIVITY OF MDV3100 IN A PHASE 1-2 STUDY OF ADVANCED PROSTATE CANCER (2010) (1)
First interim results of the Radium-223 (Ra-223) reassure observational study in metastatic castration-resistant prostate cancer (mCRPC): Safety and baseline (BL) characteristics of U.S. patients (Pts) by prior/concomitant treatment (Tx). (2018) (1)
Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts). (2014) (1)
CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC) (2009) (1)
A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2019) (1)
647 PHASE 1–2 STUDY OF MDV3100 IN PRE- AND POST-DOCETAXEL ADVANCED PROSTATE CANCER: LONG-TERM EFFICACY RESULTS (2011) (1)
Abstract 439: Targeted single cell DNA sequencing without prior whole genome amplification for mutational analysis of circulating tumor cells (2019) (1)
Duration of the first off treatment period is associated with time to androgen independence (AI) and survival in men with localized or biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation (IAD) (2007) (1)
Abstract CT134: Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment (2015) (1)
Impact of prostate cancer treatments on exercise behaviors of men attending an exercise counselling service implemented as standard care. (2018) (1)
Back to Basics: Addressing Bone Health in Men with Prostate Cancer on Androgen Deprivation Therapy. (2019) (1)
Influence of infusion duration on the efficacy and toxicity of intravenous cyclosporine in bone marrow transplant patients. (1988) (1)
Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). (2012) (1)
A phase I/II trial of CD3/CD28 activated T cells (Xcellerated T Cells) in patients with hormone refractory prostate cancer. (2004) (1)
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide (2021) (1)
Real-world experience with sipuleucel-T in patients (pts) ≥80 years old with metastatic castration-resistant prostate cancer (mCRPC): Data from PROCEED. (2013) (1)
First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC). (2021) (1)
Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer. (2009) (1)
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC. (2020) (1)
593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC) (2021) (1)
Continuous infusion 5 fluorouracil (FU) and folinic acid (FA) in disseminated colorectal cancer (1985) (1)
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer an (2016) (1)
Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study. (2013) (1)
Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421). (2012) (1)
Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL. (2016) (1)
Evaluating an educational intervention to alleviate distress among men with newly-diagnosed prostate cancer and their partners. (2017) (1)
Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer (2022) (1)
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial. (2017) (1)
Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer (1989) (1)
Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry. (2016) (1)
Abstract 305: The biological and molecular characterization of clinically relevant prostate cancer xenograft lines (LuCaP series), including responses to therapy. (2013) (1)
Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors (2021) (1)
Real-world experience of therapeutic sequencing and time to first anticancer intervention (ACI) following sipuleucel-T (sip-T): Initial data from the PROCEED registry. (2016) (1)
Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (2012) (1)
Antigen Presenting Cell (APC) Activation in Sipuleucel-T: Is Activation Increased in Earlier Prostate Cancer Disease States? (2012) (1)
Positive surgical margins: the argument for androgen deprivation and chemotherapy. (2009) (1)
Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. (2022) (1)
Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer (2021) (1)
MP49-15 DOES TUMOR MICROENVIRONMENT AFFECT THE RESPONSE OF CASTRATION RESISTANT PROSTATE CANCER TO THERAPY IN BONE VS VISCERAL METASTASES? (2014) (1)
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment (2021) (1)
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (1)
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study) (2022) (1)
Abstract 5190: Development of a multi-parameter immunofluorescence assay for identification of circulating tumor cells with epithelial-mesenchymal phenotype (2018) (1)
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. (2022) (1)
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (0)
Feasibility, Acceptability, and Clinical Significance of a Dyadic, Web-Based, Psychosocial and Physical Activity Self-Management Program (TEMPO) Tailored to the Needs of Men with Prostate Cancer and Their Caregivers: A Multi-Center Randomized Pilot Trial (2022) (0)
MP54-08 INTEGRATING SHAReCLINIC (SHARe) INTO THE PROSTATE CANCER SUPPORTIVE CARE (PCSC) PROGRAM SEXUAL HEALTH CLINIC (SHC) (2023) (0)
PSA doubling time (PSA-DT) during the “off treatment” interval in men with biochemical relapse of prostate cancer treated with intermittent androgen suppression (IAS) (2005) (0)
Abstract 406: Characterizing the molecular features of the neuroendocrine phenotype in castration resistant prostate cancer. (2013) (0)
Erratum: Hormonal therapy for prostate cancer (The Journal of Urology 173, 5 (1567)) (2005) (0)
971 SAFETY AND CHANGES IN LABORATORY PARAMETERS ASSOCIATED WITH SIPULEUCEL-T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PHASE 2 PROACT STUDY (2013) (0)
Abstract 5230: Development of a multi-parameter immunofluorescence assay for simultaneous detection of androgen receptor and androgen receptor variant 7 in prostate cancer circulating tumor cells (2018) (0)
University of Washington Prostate Cancer Clinical Trials Consortium Application (2011) (0)
Abstract 3302: Profiling prostate cancer metastases (2010) (0)
176 A Study Protocol for a Critical Appraisal of The Sexual Health Rehabilitation Action Plan (SHRAP) (2018) (0)
Abstract P1-20-02: A machine learning approach to identify risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from breast cancer (2022) (0)
Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC). (2017) (0)
Aggressive Urologic Malignancy in Heart Transplant Recipients (2010) (0)
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer (2020) (0)
Abstract 1532: The identification of osteoblastic and osteolytic factors in prostate cancer bone metastases (2012) (0)
Initial experience with sipuleucel-T (sip-T) in the immediate post-approval setting: The University of Washington (UW) experience. (2012) (0)
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer (2022) (0)
Implementation of an exercise behavior change clinic for men with prostate cancer: Baseline results. (2017) (0)
Abstract #5524: Chemotherapy-induced monoamine oxidase A expression in prostate carcinoma associates with clinical outcome and functions as a cytoprotective resistance enzyme through HIF1 pathway (2009) (0)
Reply form Authors re: Bertrand Tombal. Continuous Improvement Versus Innovation: The Case for Sipuleucel-T. Eur Urol 2012;61:648–9 (2012) (0)
P3-292: Association of apolipoprotein E and serum abeta levels in men undergoing intermittent androgen ablation (2008) (0)
Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis (2020) (0)
Abstract 3242: The molecular and biological characterization of 25 unique prostate cancer xenograft lines, including response to therapy (2010) (0)
Testosterone kinetics in the first cycle of intermittent androgen deprivation (IAD) for men with localized or biochemical relapse (BR) of prostate cancer (PC) (2008) (0)
Abstract 1989: SRRM4 and the loss of REST may promote the emergence of the neuroendocrine /neuronal phenotype in castration resistant prostate cancer (2014) (0)
Need for awareness and monitoring of ocular toxicities (OT) due to weekly docetaxel administration: experience during a trial of neoadjuvant docetaxel (D) and mitoxantrone (M) for patients with high-risk prostate cancer (PC). (2004) (0)
Retrospective mathematical analysis of serial prostate specific antigen (PSA) measurements for patients with M0 prostate cancer treated with intermittent androgen suppression (IAS). (2012) (0)
TREATMENT OF CHRONIC MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION : THE CASE FOR GIVING INTERFERON. AUTHORS' REPLY (1998) (0)
Prostate Cancer National Summit's Call to Action. (2019) (0)
Prostate Cancer Clinical Trials Consortium Clinical Research Site: University of Washington (UWash) (2019) (0)
Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry. (2018) (0)
Effects of age on outcomes in men receiving treatment for metastatic castration-resistant prostate cancer (mCRPC): Analysis of Medicare fee for service (FFS) claims data. (2020) (0)
Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity. (2010) (0)
Reply to M.A.N. Şendur et al and J. Michels. (2017) (0)
160 POSTER Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials Consortium (2008) (0)
Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data. (2020) (0)
Faculty Opinions recommendation of Barriers and facilitators related to undertaking physical activities among men with prostate cancer: a scoping review. (2021) (0)
Time to testosterone (T) and PSA rises during first “off treatment” interval (1OFF-2ON) of intermittent androgen deprivation (IAD) as prognostic for time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (2012) (0)
Cell-free circulating tumor DNA (cfDNA) to identify germline (GL) and somatic BRCA alterations (alts) in men with advanced prostate cancer (ProsCA). (2018) (0)
Partners assessment of sexual function on androgen suppression (AS) for treatment of biochemical relapse of prostate cancer (2005) (0)
MLN8237 (ALISERTIB), An Investigational Aurora a Kinase (AAK) Inhibitor, in Patients with Advanced Solid Tumors Including Castration-Resistant Prostate Cancer (CRPC) Receiving a Standard Docetaxel Regimen: Preliminary Phase 1 Results (2012) (0)
Phase I study of interleukin 2 (IL2) maintenance after induction with weekly docetaxel and estramustine in patients with metastatic hormone refractory prostate cancer (HRPC). (2006) (0)
Two-year review of the electronic Patient Reported Outcome (ePRO) system in the Prostate Clinic at the Vancouver Prostate Centre (VPC). (2019) (0)
PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
Editorial Comment. (2021) (0)
Counseling Patients on Choice of Therapy (2004) (0)
Tailoring Exercise Programming To Optimize Recruitment, Adherence And Completion Among Survivors With Brain Tumours (2020) (0)
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database. (2020) (0)
Correction to: Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors (2019) (0)
Nutrition services for men with prostate cancer: A health professional survey. (2018) (0)
Does chemotherapy have a role before hormone-resistant disease develops? (2009) (0)
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. (2016) (0)
Abstract 1118: Circulating microRNA biomarkers for cancer exist in multiple biophysical states. (2013) (0)
Abstract LB-203: Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (2008) (0)
A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway. (2020) (0)
Effect Of An Exercise Counselling Clinic On Exercise Behaviour In Men With Prostate Cancer.: 2656 June 1 4 (2018) (0)
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (0)
Utilization of the sexual health service from the prostate cancer supportive care program: A chart review. (2018) (0)
581P Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1 (2021) (0)
A randomized comparison of group mindfulness and group cognitive behavioral therapy vs control for couples after prostate cancer with sexual dysfunction. (2023) (0)
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases (2015) (0)
Exercise Counselling To Promote Exercise Behaviour Change In Individuals With Prostate Cancer (2020) (0)
TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT). (2018) (0)
Editorial Comment. (2018) (0)
High detectability of metastatic colorectal carcinoma with In-111 ZCE 025 monoclonal antibody (1986) (0)
Sipuleucel-T (2019) (0)
A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial. (2012) (0)
The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data. (2019) (0)
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial ( SWOG S 0421 ) (2018) (0)
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA. (2019) (0)
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (2021) (0)
554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies (2008) (0)
Identifying biomarkers specific to bone metastases in castrate-resistant prostate cancer. (2014) (0)
Abstract 5122: Characterizing the molecular features of ERG positive tumors in primary and castration resistant prostate cancer. (2013) (0)
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
Abstract 1583: The biological and molecular characterization of 24 unique prostate cancer xenograft lines, including responses to therapy (2011) (0)
Faculty Opinions recommendation of Prostate cancer in young men: An emerging young adult and older adolescent challenge. (2019) (0)
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry (2020) (0)
Abstract 6442: Investigation of custom biomarkers on circulating tumor cells from clinical samples using RarePlex®Developer Kits (2020) (0)
Urological cancer: α-Emitting radium-223—additional choices, more unknowns (2013) (0)
Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go? (2014) (0)
NaturallyOccurringProstateCancerAntigen- SpecificT CellResponsesofaTh1PhenotypeCanBe DetectedinPatientsWithProstateCancer (2001) (0)
Abstract C34: The biological and molecular characterization of 28 unique prostate cancer xenograft lines (LuCaP series), including responses to therapy (2012) (0)
Imaging , Diagnosis , Prognosis Genetic Pro fi ling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer (2014) (0)
Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. (2021) (0)
Sipuleucel-T (2020) (0)
Abstract 5384: Analytic validation of an assay to detect androgen receptor splice variant ARv7 protein expression on circulating tumor cells from prostate cancer patients (2020) (0)
Advancing Treatment Strategies in Metastatic Castration-resistant Prostate Cancer: The Urologists Role. (2016) (0)
Prostate cancer: Mapping the course after CHAARTED (2015) (0)
Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer (2018) (0)
MP87-16 NOVEL ANTIANDROGEN ARN-509 IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (2015) (0)
165 Results of the Critical Appraisal of the Sexual Health Rehabilitation Action Plan (SHRAP) (2020) (0)
Author ' s response to reviews Title : Changes in neuronal activation patterns in response to androgen deprivation therapy : A Pilot study (2009) (0)
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC) (2023) (0)
Abstract CN02-03: Circulating tumor cells as biomarkers in the development of the androgen receptor antagonist, MDV3100 (2009) (0)
017 Sexual Rehabilitation Recommendations for Prostate Cancer Survivors and Their Partners from a Bio-psycho-social Prostate Cancer Supportive Care Program (2021) (0)
Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling (2018) (0)
Faculty Opinions recommendation of Exercise medicine in men with prostate cancer: breaking barriers to increase participation. (2021) (0)
An environmental scan of sexual health services for cancer survivors among Canadian institutions. (2022) (0)
Patterns and predictors of attendance at a comprehensive, multi-disciplinary supportive care program for men with prostate cancer and their partners. (2018) (0)
2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen (2015) (0)
A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. (2012) (0)
Adjuvant Treatment with Alpha Interferon (IFN) for Patients at High Risk for Relapse after Allogeneic Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) (2018) (0)
014 Demographics and Characteristics of Patients Accessing a Prostate Cancer Supportive Care Program's Sexual Rehabilitation Clinic (2021) (0)
Seminar article Bone loss and the evolving role of bisphosphonate therapy in prostate cancer (2003) (0)
A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study (2016) (0)
Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. (2012) (0)
Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691). (2014) (0)
Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer (2022) (0)
Relationship of time to testosterone (T) and PSA rises during the first "off treatment" interval (1OFF) of intermittent androgen deprivation (IAD) with time to castration resistance (CRPC) and prostate cancer mortality (PCM) in men with biochemical relapse (BR). (2012) (0)
Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. (2014) (0)
Abstract 1561: Increased phenotypic depth for automated visual identification of biomarkers on circulating tumor cells by cocktailing epithelial markers EpCAM and cytokeratin (2018) (0)
Four-year overview of enrollment and participation in research studies conducted at the Prostate Cancer Supportive Care (PCSC) Program. (2019) (0)
Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
Transitional Cell Carcinoma of the Urinary Bladder: Histologic Clearance With Combined 5-FU Chemotherapy and Radiation Therapy: Preliminary Results of a Bladder-Preserving Study (1989) (0)
794PREAL WORLD DATA ANALYSIS OF INCIDENT METASTATIC (M1) PROSTATE CANCER (PC) PATIENTS (PTS): US CLAIMS DATABASE ANALYSIS. (2014) (0)
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis (2015) (0)
Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry. (2017) (0)
Risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from solid tumors: A real-world machine learning approach. (2021) (0)
A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC). (2020) (0)
A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial. (2012) (0)
External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. (2022) (0)
123 Time to disease-related pain (TDRP) following sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Integrated results from three randomized phase 3 trials (2012) (0)
Androgen Deprivation Therapy and Imaging (2017) (0)
Implementation of a disease specific survivorship program for men with prostate cancer and their partners. (2016) (0)
009 The Utilization of a Dedicated Sexual Health and Pelvic Floor Physiotherapy Service for Urinary Incontinence and Erectile Dysfunction after Prostate Cancer Diagnosis (2017) (0)
Introduction to the seminar series: Optimal management during ADT to mitigate complications. (2020) (0)
Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry. (2016) (0)
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (2020) (0)
787PDPrognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (2017) (0)
Evaluating patient out-of-pocket (OOP) costs associated with attendance at a prostate cancer supportive care program. (2019) (0)
The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective. (2013) (0)
A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer (2016) (0)
Abstract 5249: LuCaP prostate cancer xenografts: Models that allow clinically relevant investigation of prostate cancer in a preclinical setting (2012) (0)
Title : A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with 2 Metastatic Castration-Resistant Prostate Cancer 3 (2021) (0)
Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Celestia (tia) S. Higano?

Celestia (tia) S. Higano is affiliated with the following schools:

Institute of Cancer Research
Université de Montréal
University of British Columbia
Marmara University
University of California, Davis
Oregon Health & Science University
University of Washington

Celestia (tia) S. Higano's Academic­Influence.com Rankings

Why Is Celestia (tia) S. Higano Influential?

Celestia (tia) S. Higano's Published Works

Published Works

What Schools Are Affiliated With Celestia (tia) S. Higano?

Celestia (tia) S. Higano's AcademicInfluence.com Rankings